AdaptOS™ Atlas Vertical: AI in Pharma - Drug Development 2026

From hypothesis to approval: target triage, adaptive protocol simulators, external controls, DMC-governed dosing, RBQM signal mining, and clause-aware CTD/label QA—40 pilotable solutions.

Drug development scales on enrollment velocity, amendment discipline, inspection readiness, and capital efficiency. This pack tackles evidence-to-approval: multimodal retrieval for feasibility, screen-fail reduction, comparator transparency, dose governance, PV lead-time gains, portfolio cash-curve control, and payer-grade narrative conversion.

What you get: 40 solutions mapped to the AdaptOS™ Atlas locked schema to align AI adoption with your current tech stack—segment shifts, strategic imperatives, adoption sequencing, solution clusters, value-compounding paths, governance & trust anchors, risk & resistance playbooks, board-level guardrails, RFP-ready vendor-analog references (non-endorsement), KPI-anchored 90-day pilots, buyer personas, HITL boundaries, and integration/data/security notes—so you can sequence action and defend spend with evidence in 2026.